International Vaccine Institute

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Retrieved on: 
목요일, 3월 21, 2024
Control, EST, Congress, Lyme disease, CEPI, Coalition, Saint-Herblain, Pan American Health Organization, Walter, PAHO, International Vaccine Institute, Chikungunya, Epidemic, Drug, IVI, CDC, Process, VLA, Euronext Paris, Market access, ACIP, The 24th

The Company will have a display in the exhibit area of the congress at booth #433.

Key Points: 
  • The Company will have a display in the exhibit area of the congress at booth #433.
  • There will be two sessions, from 11:40 to 12:20 EST and again from 12:30 to 1:10pm EST.
  • Advisory Committee on Immunization Practices (ACIP)1 and these recommendations were adopted by the Centers for Disease Control and Prevention (CDC)2.
  • Additionally, Valneva CEO Thomas Lingelbach will present the Best Production / Process Development award at the event.

IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress

Retrieved on: 
월요일, 10월 23, 2023
FDA, Food, SARS-CoV-2, Human, Omicron, Vaccine, Science, Immune system, COVID-19, Lassa mammarenavirus, Messenger, Kinetics, Infection, Shenzhen Kangtai Biological Products, Bangladesh Technical Education Board, Safety, Wistar Institute, Cancer, International Vaccine Institute, Drug discovery, DNA, Pharmaceutical industry

LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on harnessing the power of the immune system against cancer and infectious diseases, announces that Khursheed Anwer, Ph.D., IMUNON’s executive vice president and chief science officer, will highlight the Company’s vaccine development work at the 3rd International Vaccines Congress being held in Boston October 23-26.

Key Points: 
  • Dr. Anwer will present “A DNA-based Vaccine Technology Independent of Virus or Device,” at 2:00 p.m. Eastern time on October 23rd.
  • His presentation describes the multiple advantages of the Company’s PlaCCine modality over current commercial vaccine platforms, including more durable antigen expression and T-cell responses versus protein and mRNA vaccines.
  • Compared with viral or other DNA vaccines or protein vaccines, PlaCCine vaccines have advantages in T-cell responses, safety, compliance and manufacturing flexibility.
  • “We are delighted to share our ongoing work at this important conference,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.

GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics

Retrieved on: 
금요일, 8월 25, 2023
Climate, Public, International Vaccine Institute, IVI, Cholera, UNICEF, Flood, Climate change, Developed country, MOU, WHO, Disease, Vaccine

While Eubiologics, a developer and producer of Euvichol, takes charge of the bulk vaccine production, GC Biopharma will be in charge of the packaging process including vial bottling.

Key Points: 
  • While Eubiologics, a developer and producer of Euvichol, takes charge of the bulk vaccine production, GC Biopharma will be in charge of the packaging process including vial bottling.
  • The two companies will produce the vaccine together from the first half of 2024 in order to supply to UNICEF.
  • Euvichol is an oral vaccine jointly developed by Eubiologics and International Vaccine Institute (IVI) for the prevention of cholera, a disease that is prevalent mainly in the developing countries.
  • Eubiologics in currently supplying 100% of cholera vaccines administered by UNICEF.

SK bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine

Retrieved on: 
목요일, 8월 24, 2023
MSD, Vaccine, Partnership, Joint, SK, Life, Typhoid fever, Vaccination, Diarrhea, Hilleman Laboratories, Biotechnology, Infection, IVI, Ministry of Food and Drug Safety, International Vaccine Institute, Fever Dream, World Health Organization, MFDS, Constipation, Research, Temperature, Abdominal pain, Science, Ministry, Salmonella enterica subsp. enterica, Risk, Water, Gavi, Nausea, Memorandum of understanding, Bill, Climate, Mortality, WHO, Health, Headache, Bill & Melinda Gates Foundation, Mental health, Safety, Skin, Fatigue, Disease, Pharmaceutical industry, Food, Wellcome, Rickettsia typhi

SK bioscience and Vaxxas have officially entered into a Joint Development Agreement.

Key Points: 
  • SK bioscience and Vaxxas have officially entered into a Joint Development Agreement.
  • This collaboration is set to revolutionize vaccine delivery by developing a novel vaccine-delivery device combination product using Vaxxas' high-density microarray patch (HD-MAP) platform technology with SK bioscience's proprietary typhoid vaccine.
  • Under the agreement, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid™ that was jointly developed by SK bioscience and the International Vaccine Institute (IVI).
  • SK bioscience collaborated with Wellcome and the IVI on the development of a trivalent invasive non-typhoidal Salmonellosis vaccine candidate in 2019.

Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch

Retrieved on: 
목요일, 8월 24, 2023
Biotechnology, Health, Pharmaceutical, Other Philanthropy, Philanthropy, Other Science, Research, Medical Devices, Infectious Diseases, General Health, Foundation, Science, Clinical Trials, Medical Supplies, Vaccine, SK, Typhoid fever, Vaccination, International Vaccine Institute, Water quality, COVID-19, IVI, World Health Organization, Chickenpox, Shingles, Hygiene, Trial of the century, US, Salmonella enterica subsp. enterica, Risk, Water, Bill, WHO, Bill & Melinda Gates Foundation, Safety, Disease, Pharmaceutical industry, Wellcome, Rickettsia typhi, Food

The typhoid vaccine formulation used to coat the HD-MAP will be based on SKYTyhpoid™, an approved typhoid conjugate vaccine that was jointly developed by Vaxxas’ collaborator in this project, SK bioscience, and the International Vaccine Institute (IVI).

Key Points: 
  • The typhoid vaccine formulation used to coat the HD-MAP will be based on SKYTyhpoid™, an approved typhoid conjugate vaccine that was jointly developed by Vaxxas’ collaborator in this project, SK bioscience, and the International Vaccine Institute (IVI).
  • The typhoid vaccine product candidate used in these studies will be formulated to be more stable at higher temperatures than required for needle and syringe vaccination.
  • As such, success in this endeavor has the potential to increase global access to the life-saving typhoid vaccine.
  • This project continues to build on the progress of its HD-MAP technology in human clinical studies with other vaccine candidates including COVID-19 and influenza.

Lemonex announces approval of IND application for  mRNA-DegradaBALL vaccine, LEM-mR203, phase 1 clinical trial

Retrieved on: 
수요일, 8월 9, 2023
Research, Pharmaceutical, Medical Devices, Hospitals, University, Health Technology, Education, Clinical Trials, Science, COVID-19, Biotechnology, Health, POC, Inc., IPO, Therapy, LEM, International Vaccine Institute, Ministry of Food and Drug Safety, IVI, Clinical trial, Singapore Workplace Safety and Health Conference, MFDS, Myocarditis, Multimedia, Temperature, RNA, Messenger, Small RNA, Ministry, Investigational New Drug, Microsoft, Bill & Melinda Gates Foundation, Seoul National University Hospital, Risk, Anaphylaxis, DDS, WHO, LNP, Transport, API, IND, Conference, NIH, Safety, Pericarditis, Vaccine, KOSDAQ, Food

It is possible to quickly respond to the next pandemic through pre-production, stock storage, and priority supply of DegradaBALL.

Key Points: 
  • It is possible to quickly respond to the next pandemic through pre-production, stock storage, and priority supply of DegradaBALL.
  • (Provided by Lemonex)
    LEM-mR203 is the first mRNA vaccine candidate to which Lemonex's proprietary drug delivery platform technology, DegradaBALL (DegradaBALL-mRNA system), is applied.
  • This clinical trial is for Covid-19, and safety and immunogenicity will be evaluated in healthy adults at Seoul National University Hospital, Korea.
  • The drug delivery technology of DegradaBALL developed by Lemonex may address these issues, suggesting a more advanced DDS technology for mRNA vaccines and therapeutics.

Innoviva Announces Retirement of Board Chairman

Retrieved on: 
금요일, 4월 28, 2023
Biotechnology, General Health, Pharmaceutical, Health, International Vaccine Institute, Accounting, III, Trustee, Annual general meeting, Management

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today announced that Mr. Bickerstaff would not stand for reelection at the Company’s 2023 Annual Meeting.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today announced that Mr. Bickerstaff would not stand for reelection at the Company’s 2023 Annual Meeting.
  • Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members.
  • Mr. Bickerstaff indicated that he is stepping down from the Board to focus on other professional and philanthropic pursuits, which includes his role as chair of the Board of Trustees for the International Vaccine Institute.
  • “Serving Innoviva as Board Chairman has been an honor,” said Mr. Bickerstaff.

Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA Trends

Retrieved on: 
금요일, 3월 3, 2023
Research, European, Mater Group, NEXT Woman of the Year awards, Royal college, Australasian, University of the Philippines Manila, Consultant, Senior, Editor-in-chief, Toxicology, IND, Protein, University, Royal Australasian College, Infection, COVID-19, ChromeOS, Marie Cassidy, Associate, Acquisition, Tropical medicine, Principal, Vaccine, Clinical trial, IVI, Drug development, Pharmacist, International Vaccine Institute, Licensure, SOP, Drug Development and Industrial Pharmacy, Medical microbiology, SK, Babaji, Pharmaceutical industry, Fine chemical, Pharmacology, Physician, Medicine

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
수요일, 2월 15, 2023
University of the Philippines Manila, Toxicology, International Vaccine Institute, Royal college, Marie Cassidy, Acquisition, Clinical trial, Editor-in-chief, Vaccine, Infection, SOP, Protein, SK, University, Drug Development and Industrial Pharmacy, European, NEXT Woman of the Year awards, Royal Australasian College, IVI, Babaji, Pharmacist, Licensure, Research, Mater Group, Medical microbiology, Associate, COVID-19, Principal, ChromeOS, Drug development, Tropical medicine, Senior, Australasian, Consultant, IND, Pharmaceutical industry, Fine chemical, Physician, Medicine, Pharmacology

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND submission

Retrieved on: 
화요일, 2월 14, 2023
COVID-19, Technology, Infectious Diseases, Genetics, Clinical Trials, Nanotechnology, Biotechnology, Pharmaceutical, Health, Oncology, IVI, Messenger, International Vaccine Institute, Pandemic, Therapy, Technology transfer, Intellectual property, Nanoparticle, Safety, Ministry of Food and Drug Safety, Small RNA, Clinical trial, RNA, Fibrosis, Skin, POC, Ministry, Investigational New Drug, Seoul National University, IND, Myocarditis, LNP, Inc., RNA interference, Observation, Pericarditis, Anaphylaxis, MFDS, LEM, Vaccine, Food

This clinical trial is the first mRNA vaccine to which Lemonex's proprietary drug delivery platform technology, DegradaBALL®, is applied.

Key Points: 
  • This clinical trial is the first mRNA vaccine to which Lemonex's proprietary drug delivery platform technology, DegradaBALL®, is applied.
  • It is a booster shot clinical trial for Covid-19, and safety and reactogenicity will be evaluated in healthy adults.
  • “We already confirmed the safety of DegradaBALL in healthy people through the phase 1 clinical trial of LEM-S401 (a siRNA gene therapy product).
  • siRNA gene therapy LEM-S401: Completed administration and observation of the last subject in the phase 1 clinical trial, Dual-acting RNA immuno-oncology drug LEM-S403: Production of clinical samples for clinical entry after completion of the GLP-tox studies.